News

Filter
Filter

04 / 24 / 2024

Renowned Oncologist and Cancer Researcher, Dr. Derek Raghavan, Joins Perthera as Chief Medical Officer

Mclean, VA // Perthera, the industry leader in Precision Oncology Decision Support announces that Dr. Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, founding President of the Levine Cancer Institute and former Chair and Director of the Cleveland Clinic Taussig Cancer Institute, has joined Perthera as Chief Medical Officer (CMO). Dr. Raghavan’s appointment underscores Perthera’s commitment to advancing precision oncology and transforming decision making for oncologists, especially those practicing in a community setting, who are confronted by the ever-increasing complexity in making treatment decisions. “I look forward to helping Perthera reach the full potential of their best-in-class AI-based treatment decision support […]

Read More
Precision OncologyThe Leadership Team
EIN Presswire PDF

04 / 02 / 2024

Perthera Names HealthTech and Medical Marketing Veteran, Donna Tuths, as CEO

Appointment signals new phase of expansion for Perthera, a Pioneer in Precision Oncology Decision Support MCLEAN, VA // Perthera, the industry leader in Precision Oncology Decision Support announces the appointment of industry veteran Donna Tuths as Chief Executive Officer. Ms. Tuths will lead the company’s market expansion and will continue to scale product development and new services. This appointment signals a new phase in Perthera’s commercial development following the assignment of a Category III CPT code for reimbursement in 2023. “I’m excited to join Perthera at this pivotal time to drive expansion,” said Tuths. “Perthera has a vital role to play […]

Read More
Decision SupportPrecision OncologyThe Leadership Team
EIN Presswire PDF

01 / 18 / 2024

Precision Oncology Pioneer, Perthera, Presents Latest Research at ASCO GI 2024

Chicago, IL // In advance of a new Current Procedural Terminology (CPT) Category III code that will go into effect on July 1st, Perthera, the leader in AI precision oncology solutions, introduced its latest generation of clinical support tools, including Perthera Lab Direct and Perthera RWE Navigator. As part of this new, enhanced clinician experience, Perthera Lab Direct will make it easier to order reports, delivering results faster and the Perthera RWE Navigator will provide clinicians direct access to Perthera’s powerful analytics. The Category III CPT code provides a critical pathway to reimbursement and wider adoption of AI-assisted Oncology decision support. The new multi-ordering platform and expanded analytics bench are intended to help support increased clinician demand.

Read More
AIClinical ResearchDecision SupportPrecision OncologyRWE
PR Newswire PDF

06 / 02 / 2023

At ASCO ’23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics

Chicago, IL // In advance of a new Current Procedural Terminology (CPT) Category III code that will go into effect on July 1st, Perthera, the leader in AI precision oncology solutions, introduced its latest generation of clinical support tools, including Perthera Lab Direct and Perthera RWE Navigator. As part of this new, enhanced clinician experience, Perthera Lab Direct will make it easier to order reports, delivering results faster and the Perthera RWE Navigator will provide clinicians direct access to Perthera’s powerful analytics. The Category III CPT code provides a critical pathway to reimbursement and wider adoption of AI-assisted Oncology decision support. The new multi-ordering platform and expanded analytics bench are intended to help support increased clinician demand.

Read More
AIDecision SupportPrecision OncologyRWE
PR Newswire PDF

02 / 08 / 2023

Perthera.ai Announces a Category III CPT Code from the AMA for its Patented Precision Oncology Decision Support Platform

McLean, VA // Perthera.ai, the industry leader in Oncology Decision Support, announces the release by the American Medical Association of a new Current Procedural Terminology (CPT) Category III code, 0794T, clearly recognizing the increasing importance of AI-assisted decision support in delivering precision oncology care. Perthera.ai is a pioneer in personalized AI-assisted Oncology decision support with its patented ranked therapy options presented in the Perthera Report created by our Precision Oncology Platform.

Read More
AIDecision SupportPoint of CarePrecision Oncology
NewsWires AMA Category III Codes PDF

10 / 10 / 2022

Massive Bio and Perthera.ai Partner to Empower Cancer Patients with Personalized Therapies and Accurate Trial Recommendations

New York, NY & McLean, VA // Massive Bio has announced a partnership with Perthera.ai. Perthera.ai’s ranked therapy recommendations will complement Massive Bio’s screening and analysis to aid more cancer patients in finding an appropriate clinical trial.

Partnerships
Applied Clinical Trials Business Wire

06 / 08 / 2022

ACCRU, a Cancer Research Network Operating Within the Mayo Clinic, has Officially Partnered with Perthera

A leading precision oncology company, to bring innovative clinical trials to cancer patients throughout the country in the Target Panc Program. Perthera, with its Oncology Operating System™, will serve as the centralized “Molecular CRO” under the umbrella protocol.

Partnerships
ACCRU

03 / 12 / 2020

GenomeWeb: Perthera’s Molecular Tumor Board Improves Patient Outcomes and Overcomes Barriers

New York, NY // GenomeWeb interviews Perthera CEO Gary Gregory and CMO Mike Pishvaian about the Perthera Platform’s proven results, the capabilities of Perthera’s molecular tumor board, and how precision medicine is changing the landscape of cancer care today.

Clinical ResearchDecision SupportMolecular ProfilingRWEvMTB
GenomeWeb

03 / 02 / 2020

Perthera and PanCAN Publish Pivotal Paper in Lancet Oncology Highlighting the Importance of Selecting Treatments Based on Tumor Mutations

This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients. Patients who receive precision medicine live an average of one year longer than those who do not.

Clinical ResearchPrecision OncologyRWE
The Lancet The Lancet (PDF) PDF

01 / 07 / 2020

How Perthera is Using AI and Molecular Data to Bring Precision Medicine to Oncology

Perthera CEO Gary Gregory talks with DocWire News to explain how Perthera’s Precision Oncology Platform is transforming precision medicine in healthcare today, with proven results and advanced technology.

AIMolecular ProfilingMultiomicsPrecision Oncology
DocWire

THIS IS AI-POWERED PRECISION ONCOLOGY

Contact Us